ChromaDex Corporation

NasdaqCM:CDXC Rapport sur les actions

Capitalisation boursière : US$569.5m

ChromaDex Bilan de santé

Santé financière contrôle des critères 6/6

ChromaDex possède un total de capitaux propres de $34.4M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $56.5M et de $22.2M. L'EBIT de ChromaDex est $447.0K ce qui fait que son ratio de couverture des intérêts -0.4. Elle dispose de liquidités et de placements à court terme de $32.2M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts-0.4x
Argent liquideUS$32.25m
Fonds propresUS$34.37m
Total du passifUS$22.15m
Total des actifsUS$56.52m

Mises à jour récentes de la santé financière

Recent updates

ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28
Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29
ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08
Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31
We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale

Oct 03

ChromaDex in pact to introduce anti-aging compound in Brazil

Sep 01

Ayana Bio appoints Frank Jaksch as CEO

Aug 24

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CDXC ( $52.1M ) dépassent ses passifs à court terme ( $17.7M ).

Passif à long terme: Les actifs à court terme de CDXC ( $52.1M ) dépassent ses passifs à long terme ( $4.5M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: CDXC est sans dette.

Réduire la dette: CDXC n'avait aucune dette il y a 5 ans.

Couverture de la dette: CDXC n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.

Couverture des intérêts: CDXC n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.


Bilan


Découvrir des entreprises saines